WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206127

CAS#: 622370-35-8

Description: Tradipitant, also known as VLY-686 and LY686017, is the 2nd generation neurokinin-1 receptor antagonist, which showed activity in preclinical anxiety models. LY686017 may be a possible therapy for alcoholism. LY686017 can be also served as a suitable chemical platform for future imaging ligand development.

Chemical Structure

CAS# 622370-35-8

Theoretical Analysis

MedKoo Cat#: 206127
Name: Tradipitant
CAS#: 622370-35-8
Chemical Formula: C28H16ClF6N5O
Exact Mass: 587.09476
Molecular Weight: 587.9
Elemental Analysis: C, 57.20; H, 2.74; Cl, 6.03; F, 19.39; N, 11.91; O, 2.72

Size Price Shipping out time Quantity
10mg USD 290 2 Weeks
100mg USD 840 2 Weeks
250mg USD 1450 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-02-26. Prices are subject to change without notice.

Tradipitant, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Synonym: Tradipitant; LY686017; LY 686017; LY686017; VLY 686; VLY686; VLY686.

IUPAC/Chemical Name: (2-(1-(3,5-bis(trifluoromethyl)benzyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)(2-chlorophenyl)methanone


InChi Code: InChI=1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2

SMILES Code: O=C(C1=CC=CN=C1C2=C(C3=CC=NC=C3)N(CC4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)N=N2)C5=CC=CC=C5Cl

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 587.9 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Gackenheimer SL, Gehlert DR. In vitro and ex vivo autoradiography of the NK-1 antagonist [³H]-LY686017 in Guinea pig brain. Neuropeptides. 2011 Apr;45(2):157-64. doi: 10.1016/j.npep.2011.01.003. Epub 2011 Feb 4. PubMed PMID: 21295853.

2: Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D, Gehlert DR, Marek G. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol. 2010 Feb;20(2):80-7. doi: 10.1016/j.euroneuro.2009.10.005. Epub 2009 Dec 16. PubMed PMID: 20018493.

3: Kuehn BM. Findings on alcohol dependence point to promising avenues for targeted therapies. JAMA. 2009 Apr 22;301(16):1643-5. doi: 10.1001/jama.2009.535. PubMed PMID: 19383946.

4: Mutschler J, Grosshans M, Kiefer F. [A new pharmacological treatment option for alcohol dependence discovered in transnational study: neurokinin-1 receptor antagonist as a possible therapy for alcoholism?]. Neuropsychiatr. 2008;22(4):283-5. German. PubMed PMID: 19081000.

5: Miller G. Psychopharmacology. Tackling alcoholism with drugs. Science. 2008 Apr 11;320(5873):168-70. doi: 10.1126/science.320.5873.168. PubMed PMID: 18403685.

6: George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M. Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science. 2008 Mar 14;319(5869):1536-9. doi: 10.1126/science.1153813. Epub 2008 Feb 14. PubMed PMID: 18276852.

Additional Information